Hormonal
Activation of PPAR-γ by thiazolidinedione (TZD) agonists (e.g., pioglitazone, rosiglitazone) improves insulin sensitivity and glycemic control in Type 2 Diabetes Mellitus (T2DM) by promoting lipid storage in adipose tissue, reducing free fatty acid release, and increasing adiponectin levels.
If you have Type 2 Diabetes, medications like pioglitazone work by helping your body store fat safely in your skin and fat tissue rather than in your liver and muscles. This reduces stress on your organs and helps your insulin work better. While you might gain some weight, it is often a sign that the medication is protecting your vital organs from harmful fat buildup.
Synthetic agonists are successful in insulin sensitivity by blocking the interaction of PPAR-γ with co-repressors as a result there is an increase in the accumulation of lipids in the adipose tissue and a decrease in the release of free fatty acids [68]. ... PPAR-γ triggers an increase in plasma concentrations of adiponectin, a hormone secreted from adipose tissue that is found at low levels in plasma of patients with T2DM. Overall functions of adiponectin are to increase FA oxidation in liver and skeletal muscle, improve insulin sensitivity in skeletal muscle and liver, and decrease glucose production in liver, resulting in decreased circulating FFAs and TG and glucose levels in liver [74].
Why this rating
The paper cites multiple clinical studies and established pharmacological use of TZDs, though it is a review article summarizing existing evidence rather than presenting new primary data.
Source
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Francisco Monsalve et al. · Mediators of Inflammation · 2013
DOI 10.1155/2013/549627
More from this paper
- Activation of PPAR-α by fibrates (e.g., fenofibrate, gemfibrozil) lowers triglycerides and raises HDL cholesterol by increasing fatty acid oxidation and lipoprotein lipase activity.Good
- PPAR-γ agonists reduce inflammation in macrophages and vascular cells by inhibiting NF-κB and AP-1 signaling pathways, thereby slowing atherosclerosis progression.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →